4-(4-oxopiperidin-1-yl)pyridine-2(1H)-one | 1253415-36-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(4-oxopiperidin-1-yl)pyridine-2(1H)-one
• 英文别名: 4-(4-oxopiperidin-1-yl)-1H-pyridin-2-one
• CAS: 1253415-36-9
• 化学式: C₁₀H₁₂N₂O₂
• 分子量: 192.217
• InChiKey: GXCQDSZAFVYEED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-oxopiperidin-1-yl)pyridine-2(1H)-one 在 吡啶 、 sulfur 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 2-[[5-(2-oxo-1H-pyridin-4-yl)-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl]carbamoylamino]-N-propan-2-ylbenzamide
  参考文献：
  名称：

  EP2426135

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氯-4-溴吡啶 在 palladium on activated carbon 1,3-二甲基-2-咪唑啉酮 、 盐酸 、 水 、 氢气 、 sodium hydride 、 potassium carbonate 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.17h， 生成 4-(4-oxopiperidin-1-yl)pyridine-2(1H)-one
  参考文献：
  名称：

  EP2426135

  摘要：

  公开号：

文献信息

• UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2426135A1

  公开（公告）日：2012-03-07

  Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物或其药学上可接受的盐，可抑制 PI3K 的活性，从而调节许多生物过程，包括细胞的生长、分化、存活、增殖、迁移、新陈代谢等，因此可用于疾病的预防/治疗，包括炎症性疾病、动脉硬化、血管/循环系统疾病、癌症/肿瘤、免疫系统疾病、细胞增殖性疾病、传染性疾病等。通过提供本说明书所示的脲衍生物或其药学上可接受的盐，上述问题得以解决。
• Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation
  作者：Zhengyu Wang、Xiaofan Shi、Huan Zhang、Liang Yu、Yanhua Cheng、Hefeng Zhang、Huibin Zhang、Jinpei Zhou、Jing Chen、Xu Shen、Wenhu Duan

  DOI：10.1016/j.ejmech.2017.07.051

  日期：2017.10

  Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected beta-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration. (C) 2017 Elsevier Masson SAS. All rights reserved.
• UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY
  申请人：Taniyama Daisuke

  公开号：US20120071475A1

  公开（公告）日：2012-03-22

  Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.
• EP2426135
  申请人：——

  公开号：——

  公开（公告）日：——